As previously reported, Guggenheim analyst Chris Pasquale initiated Dexcom (DXCM) with a Neutral rating. While he is bullish on the outlook for CGM adoption and Dexcom's ability to sustain a leadership position in the market, his recent survey work suggests the company could be at risk from both a share and pricing perspective as the field enters a disruptive phase with a rapid influx of new technologies. Pasquale also initiated diabetes market player Insulet (PODD) with a Buy rating and $105 price target, calling it "a good story poised to get even better as its pipeline matures." His surveys suggests Insulet is well positioned to take insulin pump share going forward, Pasquale tells investors. Also in the diabetes space, Pasquale started Senseonics (SENS) with a Buy rating and $6 price target, identifying its Eversense long-term implantable system as a differentiated new entrant into the continuous glucose monitoring market that he expects will appeal to diabetic patients.